Dermatitis after suspected imatinib-levothyroxine interaction in a patient with gastrointestinal stromal tumor.
Evangelos
E
Cholongitas
Chrysoula
C
Pipili
Konstadinos
K
Katsogridakis
Konstadinos
K
Relos
Maria
M
Dasenaki
D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D001549:Benzamides; D003875:Drug Eruptions / Q000473:pathology*; D046152:Gastrointestinal Stromal Tumors / Q000150:complications* / Q000473:pathology; D006801:Humans; D000068877:Imatinib Mesylate; D008297:Male; D010879:Piperazines / Q000008:administration & dosage / Q000009:adverse effects*; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D011743:Pyrimidines / Q000008:administration & dosage / Q000009:adverse effects*; D012867:Skin / Q000473:pathology; D013974:Thyroxine / Q000008:administration & dosage / Q000009:adverse effects*
D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D011505:Protein-Tyrosine Kinases; D013974:Thyroxine